Active Clinical Trial Studies
Find a Clinical Trial
Below is a list of currently active Phase I, II, III and IV trials. You can also search for a specific clinical trial using the field provided.
Clinical Trials match your criteria
-
Incidence of Surgical Site Complications Following Cesarean Delivery Closure Comparing Absorbable Subcuticular Staples with Conventional Closure
Incidence of Surgical Site Complications Following Cesarean Delivery Closure Comparing Absorbable Subcuticular Staples with Conventional Closure
-
LOU064: Remibrutinib vs. Teriflunomide
A randomized, double-blind, double-dummy, parallel-group study, comparing the efficacy and safety of remibrutinib versus teriflunomide in participants with relapsing multiple sclerosis, followed by extended treatment with open-label remibrutinib
-
Optimizing Pharmacist Team-Integratio for ICU Patient Management (OPTIM): an exploration of pharmacist-to-patient ratio.
Optimizing Pharmacist Team-Integratio for ICU Patient Management (OPTIM): an exploration of pharmacist-to-patient ratio.
-
Pembrolizumab vs. Observation in People with Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy.
-
Expanded Access to OKN-007 for Patients With Diffuse Midline Glioma, H3 K27-altered
Expanded Access to OKN-007 for Patients With Diffuse Midline Glioma, H3 K27-altered
-
Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial
Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial
-
Screening Protocol for Tumor Antigen Expression Profiling and HLA Typing for Eligibility Determination
A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T-Cells Expressing Enhanced TCRS in Subjects with Solid or Hematological Malignancies.
-
GEN1046 in Combination with Anticancer Agents for the Treatment of Advanced Endometrial Cancer
A Phase 2 Exploratory, Multicenter, Open-Label Trial to Determine the Safety and Preliminary Clinical Activity of GEN1046 in Combination with Anticancer Agents in Subjects with Advanced Endometrial Cancer
-
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients with TNBC Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05)
A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice in Patients with Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy
-
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination with Pembrolizumab Versus Investigator's Choice in HLA-A*02:01-positive Participants with Previously Treated Advanced Melanoma (TEBE-AM)
